Substances in the form of weak acid salts have been found to be problematic for dissolution testing. Their absorption can start only after they are turned into the form of an acid following the gastric passage although they were administered in the form of a salt. Due to poor solubility, they cannot be tested in acidic gastric environment for a biased dissolution profile. The biphasic dissolution method is promising for overcoming this obstacle. Tablets with warfarin clathrate sodium salt in two concentrations and two different particle size distributions were tested as a suitable model for finding the medium and process conditions of dissolution. The dissolution method based on the use of the upper organic layer (1-octanol) and the lower aqueous layer 0.1 mol L−1 HCl) was found suitable and discriminatory for tablets containing active substances in the form of salts of weak acids. The method also reflects physical differences in the quality of used substances.
1. United States Pharmacopoeia 38 – National Formulary 33, USP Convention, Rockville (MD) 2015, p. 3869.
2. S. Klein, The use of biorelevant dissolution media to forecast the in vivo performance of a drug, AAPS. J. 12 (2010) 397–406; DOI: 10.1208/s12248-010-9203-3.
3. Y. Qiu, Y. Chen, G. Zhang and W. Porter, Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice, Academic Press, London 2009, p. 411.
4. Sirius Analytical Instruments Ltd., New instrument for automated biorelevant biphasic dissolution and solubility testing, Eur. Pharmaceut. Rev. October 2013; http://www.americanpharmaceu-ticalreview.com/22313/news/featured-news-instrument-automated-biorelevant-biphasic-dissolution-solubility-testing/; last access date September 24, 2015.
5. A. Franc and J. Muselik, Method for Preparing Solid Drug from Warfarin Sodium Salt in Form of Isopropanol Clathrate, Involves Determining Total Weight of Solid Drug and Distribution Ratio of Warfarin Sodium Salt, Pat. CZ304136-B6, October 2013.
6. J. Muselik, A. Franc, P. Dolezel, R. Gonec, A. Krondlova and I. Lukasova, Influence of process parameters on content uniformity of a low dose active pharmaceutical ingredient in a tablet formulation according to GMP, Acta Pharm. 64 (2014) 355–367; DOI: 10.2478/ACPH-2014-0022.
7. L. M. Vercaigne and G. G. Zhanel, Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on warfarins, J. Pharm. Pharm. Sci. 1 (1998) 92–94.
8. V. R. S. Uppoor, Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations, J. Control. Release 72 (2001) 127–132; DOI: 10.1016/S0168-3659(01)00268-1.